



HHS Public Access

Author manuscript

J Clin Anesth. Author manuscript; available in PMC 2016 August 01.

Published in final edited form as:

J Clin Anesth. 2015 August ; 27(5): 371–374. doi:10.1016/j.jclinane.2015.04.003.

Single-Injection Thoracic Paravertebral Block and Postoperative Analgesia following Mastectomy: A Retrospective Cohort Study

Rishi R. Agarwal, MD¹, Anne M. Wallace, MD², Sarah J. Madison, MD³, Anya C. Morgan, MA, CCRC⁴, Edward J. Mascha, PhD⁵, and Brian M. Ilfeld, MD, MS (Clinical Investigation)⁶

¹Resident, Department of Anesthesiology, University of California San Diego, San Diego, California

²Professor, Department of Surgery University of California San Diego, San Diego, California

³Assistant Clinical Professor, Department of Anesthesiology University of California San Diego, San Diego, California

⁴Research Coordinator, Department of Anesthesiology University of California San Diego, San Diego, California

⁵Associate Staff Biostatistician, Departments of Quantitative Health Sciences and Outcomes Research

⁶Professor, In Residence, Department of Anesthesiology University of California San Diego, San Diego, California

Abstract

Background—The treatment of postoperative pain following mastectomy is an area of increasing interest as this treatment option is now considered a standard of care for those affected by breast cancer. Thoracic paravertebral nerve block (tPVB) using local anesthetics administered prior to mastectomy can theoretically provide postoperative analgesia, thereby facilitating a more comfortable and shorter hospitalization.

Methods—In this retrospective cohort study, we aimed to determine the duration and degree to which tPVB provides postoperative analgesia in patients who underwent either unilateral or bilateral mastectomy (n=182). We retrospectively examined the numeric rating scale (NRS) for pain scores recorded by nursing staff throughout individual patient hospitalizations, looking specifically at the following time points: arrival from the postanesthesia care unit (PACU) to the

© 2015 Published by Elsevier Inc.

Address for correspondence: Brian M. Ilfeld, MD, MS, Department of Anesthesiology, 200 West Arbor Drive, MC 8770, San Diego, California, 92103-8770. Telephone: (858) 481-8454; Fax: (858) 683-2003; bilfeld@ucsd.edu.

Conflict of Interest: None.

Presented, in part, as a scientific abstract at the annual meeting of the American Society of Anesthesiologists in New Orleans, Louisiana, October 11–15, 2014.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

surgical wards, noon on postoperative day one (POD1), and discharge. We also examined the number of days until patients were discharged from the hospital.

Results—Our results revealed a statistically significant decrease in NRS in pain scores for patients who had received a tPVB (n=92) on arrival from the PACU to the surgical wards (mean NRS decrease of 1.9 points; 99% CI -3.0 to -0.8; $P<0.001$), but did not show statistically significant decreases in NRS for pain scores for patients at noon on POD1 (mean NRS decrease of 0.3 points at noon on POD1, $P=0.43$) or at discharge (mean NRS decrease of 0.1 point at discharge, $P=0.65$). Moreover, use of tPVB did not have an impact on time until discharge (average decrease of 0.5 h; 95% CI -6 to +5 h, $P=0.87$).

Conclusions—Single-injection tPVB appears to provide meaningful postoperative analgesia in the immediate postoperative period after mastectomy, but not after the first day of surgery.

Background

The prevalence of breast cancer in women within the United States is over 3-million, with an annual incidence of approximately 100,000 and over 35,000 women undergoing mastectomy annually (1, 2). Pain following mastectomy is often severe (3) and described as a “continuous aching pain” the day following surgery (4). As such, adequate pain control is a primary concern for both patients and healthcare providers. In addition, postoperative opioid analgesics often induce nausea and vomiting, increasing patient discomfort as well as postanesthesia recovery room and hospitalization durations.

In contrast, there is evidence that a single-injection thoracic paravertebral nerve block (tPVB) may provide potent and safe intra- and postoperative analgesia (4, 5). A tPVB involves the percutaneous injection of long-acting local anesthetic adjacent to the peripheral nerves that innervate the breast immediately lateral to the upper thoracic vertebra, either unilaterally or bilaterally. The aim of this retrospective cohort study was to determine if—and to what degree—a single-injection ropivacaine tPVB provides postoperative analgesia following unilateral and bilateral mastectomy.

Methods

Following IRB (University of California San Diego, San Diego, California) approval, we analyzed the records of 182 patients who underwent either unilateral or bilateral mastectomy with a single surgeon at the University of California San Diego (UCSD) between the years 2009 and 2011. Prior to 2010, patients undergoing mastectomy received an opioid-based analgesic regimen. During 2010, the regional anesthesia and acute pain medicine division began providing tPVBs for patients having mastectomy. All patients received oral and intravenous opioids, as well as oral acetaminophen for analgesia, as necessary.

For subjects who had received a single-injection tPVB: With a low-frequency (5–2 MHz) curved array transducer (C60x, SonoSite MicroMaxx, Bothell, WA, USA) in a sterile sleeve, the paravertebral space between the 3rd and 4th thoracic vertebrae was identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery by a regional anesthesiology attending or fellow. A local anesthetic skin wheal was raised caudal to the ultrasound transducer. An 8.9 cm, 17 gauge, Tuohy-tip needle (Arrow International,

Reading, PA, USA) was inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Ropivacaine 0.5% with epinephrine 5 µg/mL (20 mL), was slowly injected with gentle aspiration every 3 mL.

We hypothesized that use of a single-injection tPVB would be associated with lower pain scores during hospitalization following mastectomy from arrival on the post-surgical ward through noon the day following surgery (postoperative day 1—or POD 1). Pain was recorded by nursing staff using a 0–10 Likert Numeric Rating Scale for pain (NRS; 0= no pain, 10= worst pain imaginable pain). The primary outcome measures included the NRS (1) at the time of arrival to the surgical wards; (2) at noon on POD 1; (3) the minimum NRS between those two time points; (4) the maximum NRS between those two time points; and, (5) the NRS at discharge. A secondary outcome measure was the total number of hospitalization days.

Statistical analysis

Linear regression was used to assess the association between single-injection tPVB versus no injection and postoperative NRS pain scores (at 5 times: arrival to the surgical wards, noon on POD1, minimum between these two time points, maximum between these two time points, and at discharge). For pain scores, alpha level was 0.05 overall, with significance criterion of $P < 0.05/5 = 0.01$ (Bonferonni correction) for each time point. Statistical software (SAS; Carey, NC) was used for all analyses.

Results

Between 2009 and 2011, 92 received tPVB (unilateral or bilateral) immediately prior to surgery, and 90 patients did not receive tPVB (Table 1). Use of tPVB was associated with lower pain scores on arrival to the surgical wards (mean NRS decrease of 1.9 points; 99% CI –3.0 to –0.8; $P < 0.001$; Table 2). However, by the following day at noon on POD 1 and at subsequent discharge there were no statistically significant differences between the two treatments (mean NRS decrease of 0.3 points at noon on POD1, $P = 0.43$; and, mean NRS decrease of 0.1 point at discharge, $P = 0.65$). Furthermore, use of tPVB was not associated with shorter time to discharge, with average decrease of 0.5 h; 95% CI –6 to +5 h, $P = 0.87$).

Discussion

This retrospective cohort study provides further evidence that the addition of a single-injection ropivacaine tPVB to a multimodal analgesic regimen decreases pain in the immediate postoperative period following mastectomy. However, our study reveals no analgesic benefits to single-injection tPVB the day following surgery. Our results are consistent with current data on long-acting local anesthetics like ropivacaine lasting less than 24 hours (5). Moreover, the vertical spread of local anesthetic is limited when given as a single injection, and is thus unable to provide analgesia to all of the thoracic level dermatomes involved with mastectomy (5). Both are significant limitations to single-injection tPVB that warrant discussion.

A prior randomized controlled trial (RCT) by Kairaluoma et al. provided evidence of the benefits of single-injection tPVB in reducing postoperative pain in the immediate postoperative period after mastectomy (4), while a separate RCT by Klein et al. suggested the benefit of multi-level tPVB (levels T1–T7) in reducing postoperative pain up to 72 hours postoperatively after reconstructive breast surgery (5). However, while administering local anesthetic injections at multiple levels may provide a greater degree and duration of analgesia postoperatively, doing so increases the invasiveness of the procedure as well as the likelihood of related adverse events.

The use of a continuous local anesthetic perineural infusion to complement an initial single-injection tPVB provides prolonged postoperative analgesia and addresses this issue (6). Multiple studies similarly demonstrate an advantage with femoral and sciatic nerve blocks used in conjunction with continuous local anesthetic infusions, as opposed to using single-injection nerve blocks alone (7). Moreover, patients who receive both single-injection and continuous tPVB for mastectomy exhibit a decrease in the severity of chronic pain, fewer signs and symptoms of chronic pain, and increase in physical and mental health-related quality of life (8).

Interestingly, while our study suggests that most of the benefit of single injection tPVB appears to be afforded during the day of surgery, new products are being developed that prolong the duration of local anesthetics used for single-injection regional blocks by using a liposomal suspension for drug delivery (9, 10). Such products have the potential to further enhance the efficacy of combining single-injection regional blocks with continuous peripheral nerve blocks in achieving postoperative analgesia after mastectomy, as well as other types of surgeries.

Study limitations

As with any retrospective study there is a chance that the results are biased due to unmeasured confounding variables. Nevertheless, these findings highlight the possible importance of prolonging the initial surgical nerve block with a continuous local anesthetic perineural infusion.

Acknowledgments

Financial Support: The Department of Anesthesiology, University of California San Diego (San Diego, California). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the funding entity.

References

1. Howlader, N.; Noone, AM.; Krapcho, M., et al., editors. SEER Cancer Statistics Review, 1975–2009. Bethesda, MD: National Cancer Institute; 2012.
2. Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? *J Clin Oncol*. 2010; 28:3437–3441. [PubMed: 20548000]
3. Cepeda MS, Africano JM, Polo R, Alcalá R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? *Pain*. 2003; 105:151–7. [PubMed: 14499431]

4. Kairaluoma PM, Bachmann MS, Korpinen AK, Rosenberg PH, Pere PJ. Single-injection paravertebral block before general anesthesia enhances analgesia after breast cancer surgery with and without associated lymph node biopsy. *Anesth Analg*. 2004; 99:1837–43. [PubMed: 15562083]
5. Klein SM, Bergh A, Steele SM, Georgiade GS, Greengrass RA. Thoracic paravertebral block for breast surgery. *Anesth Analg*. 2000; 90:1402–1405. [PubMed: 10825328]
6. Ilfeld BM, Madison SJ, Suresh PJ, Sandhu NS, Kormylo NJ, Malhotra N, Loland VJ, Wallace MS, Proudfoot JA, Morgan AC, Wen CH, Wallace AM. Treatment of post-mastectomy pain with ambulatory continuous paravertebral nerve blocks: A randomized, triple-masked, placebo-controlled study. *Reg Anesth Pain Med*. 2014; 39:89–96. [PubMed: 24448512]
7. Ilfeld BM. Continuous peripheral nerve blocks: A review of the published evidence. *Anesth Analg*. 2011; 113:904–25. [PubMed: 21821511]
8. Karmakar MK, Samy W, Li JW, Lee A, Chan WC, Chen PP, Ho AM. Thoracic paravertebral block and its effects on chronic pain and health-related quality of life after modified radical mastectomy. *Reg Anesth Pain Med*. 2014 Jul-Aug;39(4):289–98. [PubMed: 24956453]
9. Ilfeld BM, Malhotra N, Furnish TJ, Donohue MC, Madison SJ. Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study. *Anesth Analg*. 2013; 117:1248–56. [PubMed: 24108252]
10. Ilfeld BM. Liposomal bupivacaine: Its role in regional anesthesia and postoperative analgesia. *Advances in Anesthesia*. 2014; 32:133–47.

Highlights

- We examined patients who underwent either unilateral or bilateral mastectomy
- We determined the duration and degree that tPVB provides postoperative analgesia
- We examined the numeric rating scale for pain scores from 182 individual patient hospitalizations
- tPVB provides postoperative analgesia in the immediate postoperative period after mastectomy
- tPVB does not provide postoperative analgesia after the first day of surgery

Table 1

Baseline variables and descriptive outcome summaries.

	tPVb (N = 92)	No tPVb (N = 90)	P value
Age	51.1 ± 11.5	54.2 ± 11.7	0.077 [^]
NRS_floor arrival	1.6 ± 2.5	3.4 ± 3.1	
NRS_POD1 at noon	3.2 ± 2.5	3.2 ± 2.2	
NRS_minimum	0.3 ± 0.8	0.6 ± 1.2	
NRS_maximum	6.0 ± 2.3	5.9 ± 2.1	
NRS_at discharge	2.8 ± 2.2	2.8 ± 2.0 [*]	
Days to discharge	1.6 ± 0.7	1.6 ± 0.8	

*
n=89[^]
t-test

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Association between tPVB injection and postoperative pain scores

Outcome	Difference in means tPVB minus placebo	(99% CI)**	P-value *
NRS_floor arrival	-1.89	(-2.97, -0.82)	<0.001
NRS_POD1 at noon	-0.27	(-1.16, 0.61)	0.428
NRS_minimum	-0.29	(-0.66, 0.08)	0.047
NRS_maximum	-0.01	(-0.87, 0.85)	0.971
NRS_at discharge	-0.14	(-0.94, 0.65)	0.646

* P-values from linear regression adjusting for age and bilateral/unilateral significant if $P < 0.05/5 = 0.01$ (Bonferroni correction)

** 99% CI to maintain alpha of 0.05 across 5 time points

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Population data

	Paravertebral Block (n=92)	No Paravertebral Block (n=90)
Age (yr)	51 ± 12	54 ± 12
Unilateral mastectomy	66 (72%)	52 (58%)
Bilateral mastectomy	26 (28%)	38 (42%)

Values are reported as mean (SD) or number of subjects (percentage of group), as indicated

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript